Insulin Lispro
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using the provided report template directly — this is a single, self-contained report-generation task with no additional skill needed beyond the instructions already given.
Insulin Lispro: From Diabetes Mellitus to Autoimmune Oophoritis
One-Sentence Summary
Insulin lispro is a rapid-acting insulin analogue used to control blood glucose in diabetes mellitus. The TxGNN model’s top prediction links it to Autoimmune Oophoritis with a very high similarity score, but zero clinical trials and zero publications currently support this link, and the model’s own rationale suggests the connection reflects a shared autoimmune comorbidity pattern rather than a genuine drug-repurposing mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Diabetes Mellitus (insulin replacement therapy) — based on general drug knowledge; not confirmed by Danish licence data, as none is available in this evidence pack |
| Predicted New Indication | Autoimmune Oophoritis |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known general pharmacology, insulin lispro is a rapid-acting recombinant human insulin analogue; its efficacy in glycaemic control for diabetes mellitus is well established, but no MOA data in this evidence pack supports extrapolating a direct pharmacological effect on ovarian autoimmune disease.
The TxGNN rationale itself flags this prediction as a comorbidity association rather than a treatment hypothesis: autoimmune oophoritis and type 1 diabetes mellitus are both frequent components of Autoimmune Polyglandular Syndrome type 2 (APS-2), and likely share overlapping genetic susceptibility (e.g., HLA haplotypes). This shared-node pattern in the knowledge graph is plausible reason for the high similarity score, but there is no mechanistic evidence that insulin itself exerts a therapeutic effect on ovarian autoimmune inflammation.
It is also worth noting that TxGNN surfaced four other candidate diseases in the top 10 (thiamine-responsive dysfunction syndrome, classic stiff person syndrome, focal stiff limb syndrome, and opsismodysplasia) with very similar scores. Each carries the same underlying caveat in its rationale — the association arises from shared autoimmune, metabolic, or gene-pathway nodes (e.g., GAD65 autoimmunity, SLC19A2/insulin co-morbidity, or INPPL1–insulin-signalling pathway overlap) rather than a demonstrated treatment effect. This pattern suggests the current TxGNN output for insulin lispro should be read as a hypothesis-generation signal, not a repurposing candidate ready for evaluation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
No marketing authorisation for insulin lispro is currently recorded in this evidence pack for the Danish market (Market status: Not marketed; 0 licences on file). This may reflect a genuine absence of local Laegemiddelstyrelsen/EMA registration, or it may reflect a data-collection gap — this should be verified directly against the Laegemiddelstyrelsen product register before any downstream decision.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
(Note: this evidence pack flags the absence of SmPC-derived warnings/contraindications as a Blocking data gap — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests entirely on TxGNN’s model score (L5 — no clinical trials, no literature, no observational data), and the accompanying mechanistic rationale explicitly characterizes the drug–disease link as a comorbidity/shared-node artifact rather than a plausible pharmacological repurposing hypothesis. There is currently no basis to advance this candidate beyond hypothesis-generation.
To proceed, the following is needed:
- SmPC warnings and contraindications for insulin lispro (currently a Blocking data gap — required before any safety pre-screening, per DG001)
- Verified mechanism of action data from DrugBank or another authoritative source (currently a High-severity data gap, per DG002)
- Confirmation of Danish/EU marketing authorisation status directly from Laegemiddelstyrelsen or the EMA register
- Independent mechanistic or preclinical evidence connecting insulin signalling to ovarian autoimmune pathology, beyond the comorbidity association identified by the knowledge graph
- If pursued further, expert endocrinology/reproductive-immunology input to assess biological plausibility before any trial-stage investment
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.